News Search Results
Jun 02, 2025, 21:00 ET Sony, SCREEN, and VitroVo to Start Trial Offer of MEA System Capable of Simultaneous Measuring and Recording Data from Approximately 237,000 Electrodes
the single-cell level. It has also shown promise for applications not only in drug discovery but also in a wide variety of disciplines such as biotechnology, biomedical science, medicine, and pharmacology. The results of their research have also been applied to the development of the system.Related
More news about: Sony Semiconductor Solutions Corporation
Jun 02, 2025, 16:42 ET WACKER's BELSIL® Prototypes Take the Spotlight at NYSCC 2025
industries include healthcare, pharmaceuticals, cosmetics, construction, automotive, and food/nutrition. WACKER is a pioneer in silicone, polymer, and biotechnology solutions and the leading provider of polysilicon for semiconductor and solar applications. Media Contact:James
More news about: Wacker Chemical Corporation
Jun 02, 2025, 13:46 ET Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
June 2, 2025 /PRNewswire/ -- Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today presented promising full dose-escalation results from its Phase 1 TRIgnite-1 study
More news about: Ichnos Glenmark Innovation
Jun 02, 2025, 13:37 ET Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
June 2, 2025 /PRNewswire/ -- Ichnos Glenmark Innovation (IGI), a global, fully integrated clinical-stage biotechnology company focused on developing multispecifics™ in oncology, today presented promising full dose-escalation results from its Phase 1 TRIgnite-1 study
More news about: Ichnos Glenmark Innovation
Jun 02, 2025, 13:25 ET Freenome Announces JAMA Publication of Data from Pivotal Study of its Blood-Based Test for Colorectal Cancer
BRISBANE, Calif., June 2, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the publication of detailed results from the pivotal PREEMPT CRC study in
More news about: Freenome Holdings, Inc.
Jun 02, 2025, 10:23 ET CRISPR Market is expected to generate a revenue of USD 12.78 Billion by 2032, Globally, at 15.85% CAGR: Verified Market Research®
areas, and aligning with regulatory standards will be critical to mitigate risks and accelerate commercialization in this evolving, high-impact biotechnology landscape. LEWES, Del., June
More news about: Verified Market Research
Jun 02, 2025, 10:00 ET Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jun 02, 2025, 09:00 ET Congruence Therapeutics Announces Oral Presentation on Novel GCase Activators and Correctors for Parkinson's Disease with GBA1 Mutations at the GBA1 Meeting 2025
June 3, 2025 /PRNewswire/ -- Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of correctors for diseases of protein misfolding, including MC4R-deficient genetic obesity, GBA-driven Parkinson's
More news about: Congruence Therapeutics
Jun 02, 2025, 08:04 ET IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Jun 02, 2025, 08:00 ET Curogen Taps Industry Veteran Arvind Sood to Establish and Grow U.S. Business; Expands Global Board of Directors
June 2, 2025 /PRNewswire/ -- Curogen, one of South Korea's leading biotechnology companies focused on nanotechnology-based treatments for autoimmune diseases, today announced a series of strategic appointments that strengthen
More news about: GordonMD Global Investments®
Jun 02, 2025, 08:00 ET Sapience Therapeutics Provides Data Update from Phase 2 Trial of Lucicebtide in Patients with Glioblastoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
N.Y., June 2, 2025 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today
More news about: Sapience Therapeutics, Inc.
Jun 02, 2025, 08:00 ET Diakonos Oncology Presents Promising Phase I Results of Dubodencel (DOC1021) for the Treatment of Glioblastoma at the ASCO 2025 Annual Meeting
Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced promising results from its Phase
More news about: Diakonos Oncology
Jun 02, 2025, 08:00 ET Arthrosi Announces Multiple Presentations at the European Alliance of Associations for Rheumatology (EULAR) Congress 2025
DIEGO, June 2, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels,
More news about: Arthrosi Therapeutics
Jun 02, 2025, 08:00 ET Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jun 02, 2025, 07:59 ET SkylineDx Highlights Merlin Assay's Power to Predict Recurrence Risk of Head and Neck Melanoma Without Sentinel lymph node Biopsy at ASCO 2025
www.merlinmelanomatest.com. About SkylineDx SkylineDx is a biotechnology company focused on research and development of molecular diagnostics in oncology inflammatory, and infectious diseases. SkylineDx uses its expertise
More news about: SkylineDx
Jun 02, 2025, 07:05 ET REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202
of the webcast will be available for approximately 30 days following the presentation. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Jun 02, 2025, 07:00 ET Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase 1 clinical trial of its breast
More news about: Anixa Biosciences, Inc.
Jun 02, 2025, 06:30 ET Immunic to Participate in Investor, Scientific and Industry Conferences in June
Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today
More news about: Immunic, Inc.
Jun 02, 2025, 06:00 ET IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events
S. Hata, President and Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, BiotechnologyGoldman Sachs 46th Annual Global Healthcare Conference 2025Monday, June 9th,
More news about: IDEAYA Biosciences, Inc.
May 31, 2025, 20:00 ET Breakthrough Clinical Data for LBL-024 in First-Line Treatment of Advanced EP-NEC Unveiled at 2025 ASCO Oral Session
hepatocellular carcinoma (HCC), and gastric cancer (GC). About Leads Biolabs Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology,
More news about: Leads Biolabs
May 31, 2025, 02:17 ET Berbagai Produk ETF Tangkap Peluang Pertumbuhan di Sektor Teknologi Tiongkok yang Berkembang Pesat
KesehatanTeknologi penyuntingan gen (gene-editing) segera merombak metode pengobatan untuk kelainan genetik dan kanker. E Fund CSI Biotechnology ETF (159837) berinvestasi pada perusahaan-perusahaan yang bergerak dalam diagnostik gen, biofarmasi, dan riset biomedis mutakhir sehingga ETF ini
More news about: E Fund Management
May 30, 2025, 22:27 ET CirCode Biomed Announces FDA Clearance for IND Application of HM2002, the world's first circular RNA drug being administrated in patients
circular RNA therapy forward and providing more innovative therapies for patients." About CirCode CirCode is a clinical-stage biotechnology company specializing in circular RNA therapeutics. Leveraging strong science and deep know-how, the company has built a fully integrated and proprietary
More news about: Shanghai CirCode Biomed Co. Ltd.
May 30, 2025, 16:01 ET AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
May 30, 2025, 10:30 ET Biomarkers Market worth US$104.15 billion in 2030 with 10.8% CAGR | MarketsandMarkets™
due to its well-established healthcare infrastructure, high research and development spending, and strong presence of leading pharmaceutical and biotechnology companies. The region has a high adoption rate of advanced technologies, including next-generation sequencing and companion diagnostics, which support
More news about: MarketsandMarkets
May 30, 2025, 09:30 ET Bambusa Therapeutics Announces First Subject Dosed in Phase 1 Clinical Trial of BBT002, A Novel Platform-In-A-Molecule Bispecific Antibody for Broad I&I Conditions and U.S. FDA Clearance of IND Application for BBT001
May 30, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a clinical-stage biotechnology company developing novel biologics for inflammatory and immunological diseases, today announced that it has completed the initial dosing in healthy
More news about: Bambusa Therapeutics